JP7633159B2 - メラノーマの転移及び患者の予後を予測するための遺伝子シグネチャー - Google Patents
メラノーマの転移及び患者の予後を予測するための遺伝子シグネチャー Download PDFInfo
- Publication number
- JP7633159B2 JP7633159B2 JP2021528324A JP2021528324A JP7633159B2 JP 7633159 B2 JP7633159 B2 JP 7633159B2 JP 2021528324 A JP2021528324 A JP 2021528324A JP 2021528324 A JP2021528324 A JP 2021528324A JP 7633159 B2 JP7633159 B2 JP 7633159B2
- Authority
- JP
- Japan
- Prior art keywords
- gene expression
- individual
- itgb3
- plat
- gdf15
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862703221P | 2018-07-25 | 2018-07-25 | |
| US62/703,221 | 2018-07-25 | ||
| US201862750294P | 2018-10-25 | 2018-10-25 | |
| US62/750,294 | 2018-10-25 | ||
| US201862778777P | 2018-12-12 | 2018-12-12 | |
| US62/778,777 | 2018-12-12 | ||
| PCT/NL2019/050487 WO2020022895A2 (en) | 2018-07-25 | 2019-07-25 | Gene signatures for predicting metastasis of melanoma and patient prognosis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021531831A JP2021531831A (ja) | 2021-11-25 |
| JP2021531831A5 JP2021531831A5 (enExample) | 2022-07-28 |
| JP7633159B2 true JP7633159B2 (ja) | 2025-02-19 |
Family
ID=68242821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021528324A Active JP7633159B2 (ja) | 2018-07-25 | 2019-07-25 | メラノーマの転移及び患者の予後を予測するための遺伝子シグネチャー |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12473599B2 (enExample) |
| EP (1) | EP3827101B1 (enExample) |
| JP (1) | JP7633159B2 (enExample) |
| KR (1) | KR20210044233A (enExample) |
| CN (1) | CN113039289B (enExample) |
| AU (1) | AU2019310636B2 (enExample) |
| CA (1) | CA3107401A1 (enExample) |
| DK (1) | DK3827101T3 (enExample) |
| ES (1) | ES2966015T3 (enExample) |
| IL (1) | IL280377A (enExample) |
| WO (1) | WO2020022895A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102751357B1 (ko) * | 2021-07-16 | 2025-01-06 | 한림대학교 산학협력단 | 구강암의 임프절 전이 예측과 관련된 유전자군 |
| CA3240376A1 (en) * | 2021-12-08 | 2023-06-15 | Alexander MEVES | Assessing and treating melanoma |
| EP4445137A4 (en) * | 2021-12-08 | 2025-12-10 | Mayo Found Medical Education & Res | MELANOMA ASSESSMENT AND TREATMENT |
| WO2024108191A1 (en) * | 2022-11-18 | 2024-05-23 | University Of Virginia Patent Foundation | Machine learning approach to predicting lymph node metastases |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160222457A1 (en) | 2012-11-14 | 2016-08-04 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying malignant skin lesions |
| JP2018513159A (ja) | 2015-04-17 | 2018-05-24 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体と他の抗体の組み合わせを含む組成物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040010045A1 (en) | 2001-09-07 | 2004-01-15 | Taolin Yi | Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer |
| CA2505416A1 (en) | 2002-11-21 | 2004-06-10 | Wyeth | Methods for diagnosing rcc and other solid tumors |
| US20070154889A1 (en) | 2004-06-25 | 2007-07-05 | Veridex, Llc | Methods and reagents for the detection of melanoma |
| US20060136145A1 (en) | 2004-12-20 | 2006-06-22 | Kuo-Jang Kao | Universal reference standard for normalization of microarray gene expression profiling data |
| TW200719903A (en) | 2005-04-19 | 2007-06-01 | Combinatorx Inc | Compositions for the treatment of neoplasms |
| NZ593226A (en) | 2006-01-11 | 2012-10-26 | Genomic Health Inc | Gene expression markers (efnb2) for colorectal cancer prognosis |
| US8450057B2 (en) | 2006-08-14 | 2013-05-28 | The Brigham And Women's Hospital, Inc. | Diagnostic tests using gene expression ratios |
| PT2062049E (pt) | 2006-09-06 | 2014-07-28 | Univ California | Diagnóstico molecular e classificação de melanoma maligno |
| EP2152911A4 (en) | 2007-05-04 | 2010-05-19 | Dermtech Int | DIAGNOSIS OF MELANOMA BY NUCLEIC ACID ANALYSIS |
| EP2228457A1 (en) | 2007-08-16 | 2010-09-15 | Genomic Health, Inc. | Gene expression markers of recurrence risk in cancer patients after chemotherapy |
| CA2716357A1 (en) | 2008-03-05 | 2009-09-11 | The Regents Of The University Of California | Molecular diagnosis and classification of malignant melanoma |
| RU2011142806A (ru) | 2009-05-01 | 2013-06-10 | ОНКОЗИМ ФАРМА ИНК. (Канада) | Комбинации пентамидина для лечения рака |
| WO2012031008A2 (en) | 2010-08-31 | 2012-03-08 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
| EP2619321B1 (en) | 2010-09-20 | 2018-08-01 | Advanced Cell Diagnostics, Inc. | Biomarkers for differentiating melanoma from benign nevus in the skin |
| EP3195869B1 (en) | 2012-07-27 | 2021-09-29 | Agency for Science, Technology and Research (A*STAR) | Method of promoting wound healing |
| US20170275700A1 (en) | 2014-08-14 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying metastatic malignant skin lesions and treating skin cancer |
| AU2017261688B2 (en) | 2016-05-10 | 2022-09-29 | Mayo Foundation For Medical Education And Research | Methods and materials for staging and treating skin cancer |
-
2019
- 2019-07-25 CN CN201980062825.7A patent/CN113039289B/zh active Active
- 2019-07-25 ES ES19787488T patent/ES2966015T3/es active Active
- 2019-07-25 JP JP2021528324A patent/JP7633159B2/ja active Active
- 2019-07-25 WO PCT/NL2019/050487 patent/WO2020022895A2/en not_active Ceased
- 2019-07-25 EP EP19787488.6A patent/EP3827101B1/en active Active
- 2019-07-25 CA CA3107401A patent/CA3107401A1/en active Pending
- 2019-07-25 AU AU2019310636A patent/AU2019310636B2/en active Active
- 2019-07-25 US US17/262,175 patent/US12473599B2/en active Active
- 2019-07-25 DK DK19787488.6T patent/DK3827101T3/da active
- 2019-07-25 KR KR1020217005548A patent/KR20210044233A/ko active Pending
-
2021
- 2021-01-24 IL IL280377A patent/IL280377A/en unknown
-
2025
- 2025-09-11 US US19/326,514 patent/US20260071281A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160222457A1 (en) | 2012-11-14 | 2016-08-04 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying malignant skin lesions |
| JP2018513159A (ja) | 2015-04-17 | 2018-05-24 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体と他の抗体の組み合わせを含む組成物 |
Non-Patent Citations (6)
| Title |
|---|
| HAQQ, Christopher et al.，Proceedings of the National Academy of Sc iences of the United States of America，2005年04月26日，Vol. 102, No. 17，pp. 6092-6097，DOI: 10.1073/pnas.0501564102 |
| JAEGER, Jochen et al.，Clinical Cancer Research，2007年02月01日，Vol. 13, No. 3，pp. 806-815，DOI: 10.1158/1078-0432.CCR-06-1820 |
| MEVES, Alexander et al.，Journal of Clinical Oncology，2015年08月10日，Vol. 33, No. 23，pp. 2509-2515，DOI: 10.1200/JCO.2014.60.7002 |
| RIKER, Adam I. et al.，BMC Medical Genomics，2008年04月28日，Vol. 1, Article No. 13，DOI: 10.1186/1755-8794-1-13 |
| SINGH, R. K. et al.，Melanoma Research，1999年08月，Vol. 9, No. 4，pp. 383-387，DOI: 10.1097/00008390-199908000-00007 |
| SINGH, Seema et al.，Future Oncology，2010年01月，Vol. 6, No. 1，pp. 111-116，DOI: 10.2217/fon.09.128 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20260071281A1 (en) | 2026-03-12 |
| JP2021531831A (ja) | 2021-11-25 |
| AU2019310636B2 (en) | 2025-06-26 |
| DK3827101T3 (da) | 2023-12-11 |
| US12473599B2 (en) | 2025-11-18 |
| EP3827101A2 (en) | 2021-06-02 |
| CN113039289A (zh) | 2021-06-25 |
| CA3107401A1 (en) | 2020-01-30 |
| ES2966015T3 (es) | 2024-04-17 |
| AU2019310636A1 (en) | 2021-02-04 |
| NZ771988A (en) | 2025-02-28 |
| US20210301353A1 (en) | 2021-09-30 |
| WO2020022895A3 (en) | 2020-04-02 |
| EP3827101B1 (en) | 2023-11-08 |
| IL280377A (en) | 2021-03-25 |
| WO2020022895A2 (en) | 2020-01-30 |
| KR20210044233A (ko) | 2021-04-22 |
| CN113039289B (zh) | 2025-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260071281A1 (en) | Gene signatures for predicting metastasis of melanoma and patient prognosis | |
| US20220090206A1 (en) | Colorectal cancer recurrence gene expression signature | |
| US7537894B2 (en) | Methods and kits for monitoring Barrett's metaplasia | |
| AU2020202536B2 (en) | Methods For Predicting Risk Of Metastasis In Cutaneous Melanoma | |
| JP2008536488A (ja) | 遺伝子発現署名を使用する、癌による死亡および前立腺癌生存率を予測するための方法および組成物 | |
| JP2016500512A (ja) | 肝臓サンプルの分類ならびに限局性結節性異形成、肝細胞腺腫および肝細胞癌の診断のための新規方法 | |
| US20180230545A1 (en) | Method for the prediction of progression of bladder cancer | |
| US10597728B2 (en) | Methylation site regulating expression of mda-9/syntenin | |
| CN116936086A (zh) | 乳腺癌远端转移风险预测基因模型的建构方法和风险预测方法 | |
| CN111315897B (zh) | 用于黑素瘤检测的方法 | |
| HK40046957B (en) | Gene signatures for predicting metastasis of melanoma and patient prognosis | |
| HK40046957A (en) | Gene signatures for predicting metastasis of melanoma and patient prognosis | |
| JP2021519070A (ja) | Ｔｍｐｒｓｓ２−ｅｒｇ融合状態により選択された、ｐｄｅ４ｄ変異発現、及び術後の臨床変数に基づく、術後リスクの層別化 | |
| CN116926190A (zh) | 测量乳腺癌远端转移风险的预后标志物及其应用 | |
| WO2013077859A1 (en) | Gene expression signature for the prognosis of epithelial cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220720 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220720 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230615 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230620 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230920 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231020 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240119 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240328 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240423 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240730 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241028 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250128 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250206 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7633159 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |